Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts

Inclusion Criteria

• Past prior screening mammography (SM) interpreted as negative or benign (This screening must have been performed at Mayo Clinic Rochester, Minnesota).
• Past prior SM interpreted as heterogeneously dense or extremely dense (This screening must have been performed at Mayo Clinic Rochester, Minnesota).
• Women younger than 50 years who had not undergone prior mammography, as most of these women have dense breasts.
• Subjects had to have at least one of the following risk factors:
• Known mutation in breast cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2)
• History of chest, mediastinal, or axillary irradiation
• Personal history of breast cancer
• History of prior biopsy showing atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, or atypical papilloma
• Gail or Claus model lifetime risk greater than or equal to 20%
• Gail model 5 year risk greater or equal to 2.5%
• Gail model 5 year risk greater or equal to 1.6%
• One first-degree relative with history of breast cancer
• Two second-degree relatives with history of breast cancer

Exclusion Criteria

• They are unable to understand and sign the consent form
• They are pregnant or lactating
• They are physically unable to sit upright and still for 40 minutes.
• They have self-reported signs or symptoms of breast cancer (palpable mass, bloody nipple discharge, axillary mass etc.).
• They have had needle biopsy within 3 months, or breast surgery within 1 year prior to the study.
• They are currently taking tamoxifen, evista (raloxifene), or an aromatase inhibitor for adjuvant therapy or chemoprevention.